Search Results for: Copaxone

By Shai Genish On Thursday, October 26th, 2017

The UK court overturned Teva’s Copaxone patent

  The British Supreme Court ruled Thursday in favor of Mylan and its Dutch partner Synthon, and canceled all Teva’s Copaxone for 40 mg in the country based on obviousness. A statement by Mylan believes More...

By Jewish Business News Correspondent On Tuesday, September 29th, 2015

Teva receives approval to market Copaxone in Japan

  Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) announced today that the the Japanese Ministry of Health, Labour and Welfare has approved once-daily Copaxone (glatiramer acetate injection) More...

By Niva Goldberg On Thursday, June 18th, 2015

U.S. court invalidates Teva’s Copaxone patent

The U.S. Court of Appeals has again ruled that Teva Pharmaceuticals Industries Ltd.’s patent for its top-selling multiple sclerosis treatment Copaxone is invalid. A Teva spokeswoman said that the company is “committed More...

By Ilan Shavit On Monday, March 30th, 2015

Teva Buying Auspex for $3.5 Billion in Anticipation of Competition over Copaxone

Read also: CEO Vigodman In Race To Save Teva Through ‘Inorganic Growth’ Just as JBN predicted (along with everybody else in the business) Teva Pharmaceutical Industries Ltd. Decided to buy a major generic drug More...

By Shiri Habib-Valdhorn On Tuesday, January 27th, 2015

Teva rivals urge US court to expedite Copaxone suit

Copaxone’s patent remains in force at least until the Federal Circuit Appeals Court reconsiders the case. The rivals of Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) who are developing a generic More...

By Nadav Neuman On Wednesday, January 21st, 2015

US Supreme Court upholds Copaxone patent

The ruling means Teva’s flagship multiple sclerosis treatment’s patent remains valid until September 2015.   The US Supreme Court has ruled in favor of Teva Pharmaceutical Industries Ltd. (NYSE: More...

By Koby Yeshayahou On Wednesday, December 17th, 2014
1 Comment

Brokerage Upgrades Teva Recommendation following Copaxone Dosage Change

– “We are upgrading our recommendation for Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) from “Market perform” to “Market outperform” with a target price of $62 More...

By Shiri Habib-Valdhorn On Sunday, November 30th, 2014

FDA again delays decision on Copaxone patent

– The decision gives Teva more time to transfer patients to its better patent protected double dosage Copaxone. – Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) has filed a petition at More...

By Gil Tanenbaum On Thursday, November 13th, 2014

Teva’s MS Drug Copaxone Looking for Approval in Japan

Teva’s Copaxone, a new medication under development for the treatment of multiple sclerosis treatment Copaxone, has gotten closer to getting approval for marketing in Japan from that nation’s regulatory More...

By Jewish Business News Correspondent On Thursday, September 11th, 2014

Teva finds double-dose Copaxone halves side-effects

– A 50% reduction in adverse side-effects was reported with the three-times-a-week 40 mg MS injection. – – Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) has published results of More...

Wordpress site Developed by Fixing WordPress Problems